Summary. DNA amplification by the polymerase chain reaction (PCR) is a promising method for the detection of Pneumocystis carinii in immunosuppressed patients. The sensitivity and specificity of the PCR technique has been assessed in comparison with the immunofluoresence method (IF) on bronchoalveolar lavage fluid (BALF). Results correlated in 43 (78.8 O h ) of 52 cases studied. P. carinii PCR gave positive results with BALF from all 32 patients found to have P. carinii pneumonia (PCP); IF gave positive results with 26 of them. PCR was more sensitive and as specific as IF. However, at the present time, we do not believe that it is clinically useful for detection of P. carinii in BALF samples. P. carinii DNA amplification by PCR should be reserved for testing IF-negative BALF samples from patients judged clinically to have PCP.
Introduction
Pneumocystis carinii pneumonia (PCP) is one of the most frequent opportunist infections in AIDS patients. Although its incidence is declining and its mortality rate is decreasing, PCP still represents a crucial event during AIDS disease.l The extensive use of prophylaxis has changed the clinical presentation of PCP.2-5 Thus, it is important to have a method for the detection of P. carinii infection in HIV-infected patients on prophylaxis, when micro-organisms in the bronchoalveolar lavage fluid (BALF) are very few and show some staining peculiarities, and the clinical features of PCP are unusua1.2i6 Moreover, a rapid, sensitive and specific diagnostic technique is required for the detection of P. carinii infection in patients with only mild symptoms of respiratory failure.
Recently, Wakefield et al. have developed a highly specific and sensitive technique for the identification of P. carinii by polymerase chain reaction (PCR) amplification of DNA in BALF' and induced sputum.' A strong signal in the PCR (ethidium bromide and oligoblotting positive) was consistent with a diagnosis of PCP; a weak signal (oligoblotting positive alone) indicated subclinical pulmonary coloni~ation.~
The primary aim of our study was to assess the sensitivity, specificity, positive predictive value, nega-tive predictive value and accuracy of the PCR technique on BALF as compared to the indirect immunofluorescence (IF) method for the detection of P. carinii infection in immunosuppressed patients. A secondary aim was to investigate the relationship between the result of a "quantitative" PCR for P. carinii and the clinical presentation of PCP.
Materials and methods

Patients and clinical specimens
BALF samples were obtained from 52 immunosuppressed patients (39 male, 13 female; age range 24-58 years) at the Department of Infectious Diseases, Universita Cattolica, Rome; 48 had HIV infection. three were being treated for lymphoma and one was hypogammaglobulinaemic (with a selective deficit of IgA and IgM). Forty-nine patients underwent bronchoscopy for an acute respiratory illness (fever, cough, shortness of breath) with one or more of the following features : abnormal chest signs, arterial hypoxaemia, abnormal chest X-ray. Three HIV-infected patients underwent bronchoscopy to investigate the presence of a pulmonary Kaposi's sarcoma.
Bronchoalveolar lavage was performed by two different operators who used the same technique :lo 10 ml of lukewarm saline (NaCl 0-9 YO) were instilled into the middle lobe and the lingula with an Olympus fibre-optic bronchoscope; after 60 s, a lavage sample was recovered corresponding to 5 0 4 5 % of the instilled volume. BALF samples were processed for microbiological and cytological analysis and a sample was stored at -20 "C until required for PCR.
Indirect immunojluorescen ce
Indirect immunofluorescence (IF) with monoclonal antibodies (MAbs) specific for antigens of the cyst wall (Monofluokit P. carinii, Diagnostics Pasteur, Paris, France) was performed according to the manufacturer's instructions. The dried smears were overlaid with 20 pl of trypsin and incubated at 37°C for 30 min in a humidified chamber. They were rinsed and then overlaid with 20 pl of anti-P. carinii mouse MAb. The slides were incubated at 37"C, rinsed and overlaid with 20 pl of fluorescein isothiocyanate-conjugated antimouse antibody. After a final rinse, the smears were examined by fluorescence microscopy. The IF test was considered to be positive if five or most cysts were detected on a smear.
P. carinii DNA amplijication by PCR
Briefly, 20 p1 of BALF samples were digested with proteinase K (Sigma; 0.5 mg/ml final concentration) in the presence of 10 mM Tris-HCl (pH %3), 50 mM KCl, 1.5 mM MgC1, and SDS 0.25 % for 2 h at 56°C. In 20 cases, phenol-chloroform extraction and ethanol precipitation' was also performed but no appreciable advantage was observed with this protocol and it was not used with the remaining 32 specimens; when this step was omitted, proteinase K was inactivated by heating the digested samples at 95°C for 10min. A 45-pl volume of buffer containing 100 mM Tris-HC1 (pH 8.3), 500 m M KCl, 15 m~ MgCl, and gelatin 0.01 O/O w/v was added; 5 pl of this mixture (equivalent to 1 p1 of a clinical specimen) was used for DNA amplification. An oligonucleotide primer pair (pAZ 102-E and pAZ102-H). which amplifies a P. carinii DNA sequence of part of the gene coding for the large subunit of mitochondria1 ribosomal RNA,', l 2 was used. Oligonucleotides were synthesised at the Institute of Genetics, Universita Cattolica, Rome. For amplification, 100 pmol of primers were used in a 100 pl volume of amplification buffer containing (final concentrations) 10 mM Tris-HC1, 50 mM KCl, 4 mM MgCI,, 0.2 mM dNTPs (Perkin Elmer-Cetus, Norwalk, CT, USA), Taq DNA polymerase (Perkin ElmerCetus) 2-5 units. A *'hot start" technique was used and 38 cycles of 94°C for 90 s (denaturation), 55°C for 90 s (annealing) and 72°C for 2min (extension), with a final extension at 72°C for 5 min, were performed in a thermal cycler (Perkin Elmer-Cetus).
A 5-pl volume of amplification solution was electrophoresed in an agarose 2% gel containing ethidium bromide 0.5 pg/ml and the 346-bp amplification product was visualised with an ultraviolet transilluminator.
The amplification product was also blotted on to a nylon filter (Hybond N, Amersham, Sydney, Australia) and hybridised with a 32P 5I-end-labelled oligonucleotide specific for human derived P. carinii.'* l3 After high stringency washes, the product was visualised by overnight exposure to an XAR-5 film (Eastman Kodak, Rochester, NY) at -70°C with intensifying screens.
The sensitivity of the technique was tested by adding serial dilutions of murine P . carinii organisms to a PCR-negative BALF. The cyst: trophozoite ratio of the preparation was found to be 1 : 10 based on Giemsa staining and the average number of nuclei was 1.44 x * 106/pl. Samples were processed as above, and the amplification product was electrophoresed on an agarose 2 YO gel containing ethidium bromide. The amplification product was blotted and hybridised with an anti-sense oligonucleotide (5'-CCA GCT ATA TCC TAG TCC GA-3') specific for both rat and human derived P . carinii.13 A signal was detectable for samples containing 2 10 nuclei/pl of BALF by ethidium bromide and >, 1 nucleus/pl of BALF by oligoblotting.
All pre-PCR steps were performed in a laminar flow cabinet, and laboratory procedures to avoid contamination were strictly applied. All experimental stages were performed in duplicate ; multiple negative controls (including bronchoscope washing fluid) were included in each amplification run.
Statistical methods
Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PCR and IF results for the detection of P. carinii in BALF were calculated from a 2 x 2 table.14 The statistical significance of differences in the sensitivities and specificities of the two methods was calculated by McNemar's test.15
Results
On the basis of clinical data, response to treatment and results of laboratory investigations (including IF for P. carinii and microbiological and cytological investigations on BALF and post-mortem lung samples), the 52 patients were classified as follows: group A-26 immunosuppressed patients (24 HIVpositive and two HIV-negative) with P . carinii pneumonia diagnosed by I F and response to treatment; group B-four patients (three HIV-positive and one HIV-negative) with P. carinii pneumonia diagnosed by response to treatment but I F negative; group C-two HIV-positive patients with P. carinii pneumonia diagnosed by autopsy but IF negative and response to treatment not evaluable ; group D-17 patients (1 6 HIV-positive and one HIV-negative) without P. respiratory disease; group E-three patients (HIVpositive) with negative IF and response to non-specific treatment (table I) . Thus, 32 patients (groups A+B+C) were ultimately found to have PCP; 28 of them experienced a first episode of PCP (six were on prophylaxis), and the remaining four experienced a relapse 3-16 months after initial PCP diagnosis. Of the 20 patients judged to be free of PCP (groups D + E), 13 were on specific prophylaxis.
The results of P . carinii DNA amplification are reported in table I. Samples from all patients with PCP gave positive results by P . carinii DNA amplification by PCR (by oligoblotting, with or without ethidium bromide) ; samples from 17 patients without PCP gave negative results by PCR (both ethidium bromide and oligoblotting). Samples from three patients judged to be free of PCP gave positive results by PCR after oligoblotting. The first of these patients died from a heroin overdose and autopsy was not available; however, pulmonary disease was attributed to Mycobacterium tuberculosis (identified on BAL) and disseminated Staphylococcus aureus infection with lung micro-abscesses. The second patient died from respiratory and myocardial failure probably due to M . tuberculosis, 4 months after BAL; he was receiving anti-P. carinii prophylaxis with co-trimoxazole (one double-strength tablet every second day) ; autopsy not authorised. The third patient, an intravenous drug abuser and a smoker (> 25 cigarettes daily) who suffered from recurrent episodes of bacterial pneumonia, remained alive; 10 months after BAL, a chest X-ray showed a pattern of chronic bronchitis; subsequently feeling well and on PCP prophylaxis with pyrimethamine (50 mg weekly) and dapsone (50 mg daily), her CD4+ cell count was 138/mm3.
In Ethidium bromide staining detected a large number of samples that gave positive results by oligoblotting with a sensitivity of 74.3 YO, specificity of loo%, a positive predictive value of loo%, a negative predictive value of 65.4 O/ O and an accuracy of 82.7 YO.
Discussion
The choice of a diagnostic test is based on multiple factors, including the patient population, the volume of specimens being tested by the laboratory and the level of technical expertise required. Recently, Wakefield t t al. ' .' were able to detect P. carinii by PCR amplification of specific DNA in specimens (BALF and induced sputum) that were negative by silver staining. The amplification method is likely to be more efficient than IF, which requires a minimum number of P. cwl'nii to give a positive result," but results are still not conclusive. Indeed, Lipschik et aZ.18 reported that PCR was not significantly better than the conventional staining methods in BALF. PCR for P. carinii has been shown to be specific without cross-amplification of non-specific Moreover, Peters et aZ.' suggested that a "strong" PCR signal was consistent with clinical diagnosis of PCP in immunosuppressed patients.
Our study confirmed that PCR was a very sensitive method for detection of P. carinii from one patient to another could occur during hospitalisation and room-sharing, or from close contact in the community. Furthermore, two other patients, with previous PCP, were PCR-negative for P.
carinii. These observations, combined with the failure to detect P. carinii-specific DNA in post-mortem lungs from non-immunosuppressed individuals,20 suggest that recurrent PCP may occur from re-infection rather than reactivation of latent organisms ; also, sporadic PCP may occur in immunosuppressed HIV-negative2" 22 patients or in adults without predisposing illnesses.23
In conclusion, we compared the presence of P. carinii more efficiently than IF. The specificity of the two techniques was quite high, particularly in immunosuppressed patients with PCP. Nevertheless PCR has several technical disadvantages and, currently, we do not believe that it is clinically useful for the routine detection of P. carinii in BALF. In our opinion, P.
carinii-specific DNA amplification should be used only to test IF-negative BALF samples from patients judged clinically to have PCP. The next step will be to improve the sensitivity (and thus the predictive value) of ethidium bromide staining; preliminary results (unpublished data) suggest that a "nested" PCR could be almost as sensitive and specific as oligoblotting for the detection of P. carinii. With future improvements in convenience and processing time, PCR could
